FCGR3A and pancreatic adenocarcinoma: All cholangiocarcinoma, liver hepatocellular carcinoma, pancreatic adenocarcinoma pheochromocytoma and paraganglioma, diffuse large B-cell lymphoma, ovarian serous cystadenocarcinoma, thymoma, and mesothelioma cases with genetic alteration had FCGR3A amplification.